• Permits obtained for importation of cannabis into Australia
• PreveCeutical conducting research at University of Queensland for cannabinoid-based Sol-gel products
• Cannabis-based Sol-gel products targeted at relieving symptoms such as pain, inflammation, seizures and neurological disorders

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), a health sciences company aiming to become a preventive health sciences leader, has announced the grant of three permits from the Australian government’s Department of Health allowing for the importation of cannabis into Australia for purposes of research. The permits, which have been granted to the Pharmacy Australia Centre of Excellence (PACE) at the University of Queensland, will allow PACE to import cannabis plant material shipments for research purposes. Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (FSE: 21P) (WKN: A1C4WM) will export the cannabis to PACE and has obtained the necessary Canadian permits to do so. Once shipped by Aurora, the cannabis will be used in PreveCeutical’s drug delivery research program for its Sol-gel (soluble gel).

The Sol-gel drug delivery research program, which is being undertaken at the University of Queensland, targets the development of a system that will enhance the bioavailability of drugs using a nose-to-brain delivery system. The program is being conducted by PreveCeutical’s research partner, UniQuest Pty Inc., and is being led by PreveCeutical Chief Research Officer Dr. Harendra Parekh.

The intention of PreveCeutical is to apply its Sol-gel technology to cannabinoids for the development of therapies to relieve a variety of symptoms, including pain, inflammation, seizures and neurological disorders. The permits obtained by PACE will allow PreveCeutical to test various cannabis strains for the development and commercialization of cannabinoid-based Sol-gels. Sol-gels boast a variety of advantages over traditional liquid nasal sprays, offering longer therapeutic effects, lower dosage requirements and a reduction in irritation and other unwanted side effects.

In consideration of its cannabis shipment for the research program, Aurora Cannabis has been granted certain rights, including an option to either license (on a nonexclusive basis) the Sol-gel technology for Canada and Australia or to choose a royalty arrangement on product sales, along with an option to purchase PreveCeutical shares. Part of Aurora’s strategy in becoming involved with PreveCeutical’s initiatives is gaining access to cannabis-based products that are more narrowly targeted at specific therapeutic areas but with a higher value add.

For more information, visit the company’s website at www.PreveCeutical.com

Let us hear your thoughts: PreveCeutical Medical Inc. Message Board

• Graphite is key to clean technology, such as solar energy in homes and electric cars, per Bloomberg report
• As demand increases, graphite prices projected to continue rising in 2018
• GRXXF begins drilling on property in Southern Quebec after promising assay findings show up to 22 percent high-grade large flake graphite in site samples

Graphite Energy Corp. (CSE: GRE) (OTC: GRXXF) (FWB: GOA) has started drilling on its Lac Aux Bouleaux (“LAB”) graphite property located in Southern Quebec. Commencement of these operations follow shortly after the company received promising assay results confirming the presence of high-grade large flake graphite.

Graphite is an important element in electric cars and is key to lithium-ion battery technology, as well to fuel cells and nuclear and solar power. Demand for the mineral, also used in the automotive and steel industries, is rising globally. In addition, it is used in robotics manufacturing and in desalination plants. GRXXF believes that natural jumbo flake graphite is of special demand. A recent Bloomberg article points to graphite use in home battery packs for solar roof panels for companies such as Tesla. As a result, graphite is finding its role in the development of clean technology (http://ibn.fm/eHjc1).

GRXXF is a Canadian company that explores mineral properties in Canada. It holds the right to acquire 100 percent interest in the LAB graphite property, subject to royalties. The company has commenced core drilling at the property based on the promising assay results. During the assay, a graphite pit was found indicating historical extraction of graphite from the property. Other drill holes were also located on the property, the company said.

The assay results found in mineralized samples from several locations at the LAB property included graphite carbon (Cg) up to 22.3 percent. GRXXF said that the assay results confirm its initial thoughts about the presence of high-grade flake graphite and warrant further drilling and exploration on the property (http://ibn.fm/RN5zs).

Investing News reports that prices of fine flake graphite increased by 36 percent to $863 per ton, while medium size flake graphite grew 31 percent to reach $953 per ton last fall — the first price increase for graphite since 2016. Large flake graphite rose 25 percent to $998 per ton (http://ibn.fm/0T8VS). Investing News quotes research firm Roskill as saying that higher prices will continue in 2018.

For more information, visit the company’s website at www.GraphiteEnergyCorp.com

• Company has added CNBC personality Jon Najarian to its board of directors and various committees
• Net Element is furthering plans for a decentralized blockchain platform
• Company entered 2018 with its strongest-ever balance sheet

Adding some notable star power and financial prowess to its board of directors, global technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) recently announced the appointment of Jon “Dr. J” Najarian to its board of directors (http://ibn.fm/p1MaV). In addition to serving on Net Element’s board, Najarian will serve the company as a member of its audit, compensation, nominating and corporate governance committees.

Najarian, who is a professional investor, money manager and media analyst, is a cast member of the ‘Halftime Report’ and ‘Fast Money’ programs on CNBC and was formerly a linebacker for the Chicago Bears. Among his many accomplishments, he co-founded Investitute LLC, optionMONSTER and tradeMONSTER; founded Mercury Trading; and serves as host of the International ICO Channel. He is additionally featured in the ‘DRJ Report’ on CBOE-TV.

Regarding his appointment to Net Element’s board of directors, Najarian commented that he has been impressed with the company’s technologies, as well as its endeavors to disrupt the payments industry with innovations and value-added services, including recently announced plans for a decentralized blockchain platform.

As Net Element moves forward with its corporate initiatives, Najarian’s considerable expertise in finance, capital markets, cryptocurrency and blockchain will be invaluable to the company. Net Element continues a strong forward march in 2018, supported by the strongest balance sheet the company has ever had, and it is positioned for growth as it continues to execute on promising opportunities.

Hailed as one of Deloitte’s ‘2017 Technology Fast 500™’ and one of the fastest-growing technology companies of 2016 by South Florida Business Journal, Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprises in the United States and select emerging markets. Domestically, the company endeavors to grow transactional revenue by innovating SME productivity services through blockchain technology solutions and Aptito, its cloud-based restaurant and retail point-of-sale solution. On an international level, the company is leveraging its omni-channel platform to offer flexible services to emerging markets with varied banking, regulatory and demographic conditions.

For more information, visit the company’s website at www.NetElement.com

• CEO Chris Bunka says in audio interview that human study of company’s proprietary TurboCBD technology will start in April outside of North America
• Hopes to add 6-12 more IP technology licensing contracts within year
• Cutting-edge research designed to attract the attention of tobacco and cannabis industries

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent audio interview that, although consumer products will always be important to LXRP, he estimates that up to 80 percent of its revenues could be generated through the licensing of its proprietary technology to other companies (http://ibn.fm/2jEeP).

LXRP is a British Columbia, Canada-based bioscience company that is a drug delivery platform innovator. The company has developed its patented DehydraTECH™ delivery technology platform, which it out-licenses to promote healthier ingestion methods and lower overall dosing.

Bunka said that LXRP believes that 6-12 more licensing contracts will be signed this year, both generating more revenue for the company and building greater shareholder value. “We’ve only just graduated from the demonstration phase,” he explained in the interview.

“The latest contracts are typically six figure contracts in the first year and potentially seven figure contracts over the life of the contracts,” Bunka added. “They’re becoming bigger.” The company sees a potential game changer for itself in three new sets of studies and believes that each could be material to the valuation of the company.

The first is a completed study of the company’s proprietary DehydraTECH in the form of a topical cream for the absorption of cannabidiol (CBD) through human skin (http://ibn.fm/8UGhl). LXRP said that results showed significant increases in quantity and speed of CBD absorption through the skin when compared to other formulations.

The second is a lab animal study that tests nicotine absorption. Using lab rats, the study measures gastrointestinal distress (http://ibn.fm/u3O0e). It will take blood and tissue samples at pre-prescribed time intervals to measure nicotine absorption. It will test LXRP’s ‘Trojan horse’ technology that may hide it from a negative response triggered by the body, Bunka said. An end goal is to bypass liver absorption and help avoid kidney and liver diseases associated with some of these substances by using LXRP technologies.

The third is a clinical human study first started with a Canadian University. Now, it has been moved out of North America into another institution, and the study’s initiation is imminent, he added. The study is on the cardiovascular and health effects of the company’s TurboCBD™ (http://ibn.fm/YxoSt). Bunka at the time said that the study would permit LXRP to custom design products that would increase the performance its technology already offers to customers.

“That study is now back on track. We expect it to begin in the month of April in a different location,” Bunka noted.

He added that all three studies, or any one of them, could mean a major change for the company, as its IP and studies attract increased interest from both the tobacco and cannabis industries. Lexaria has developed cutting-edge technologies with commercial application, he said in the interview.

“Those three studies, each one of those, has the potential to be a real game changer in the valuation of the company,” Bunka said.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Spending on legal cannabis worldwide expected to hit $57 billion by 2027
• Canadian government preparing to legalize cannabis-infused edibles and beverages by mid-2019
• Investments into cannabis-related companies topped $1.2 billion over first five weeks of 2018

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P), a vertically-integrated cannabis company with strategic investments in proven, revenue-generating businesses, is building a diversified portfolio that includes marketing a wide range of high quality, medicinal grade cannabis products with tremendous promise for both human and veterinary use. Liberty Leaf and its wholly owned subsidiary, North Road Ventures, recently signed an agreement with Cannabis Compliance Inc. (“CCI”) to establish Good Manufacturing Practice (GMP)-compliant processes and procedures in producing its finished products (http://ibn.fm/5Z9Cc).

“We are extremely excited to be working with CCI in establishing GMP manufacturing capabilities in-house,” Robert Jackman, scientific project manager/fulfillment for Liberty Leaf, stated in a news release. “This opens the door for North Road to obtain industry certification and regulatory authorization and/or licensing, as needed. It facilitates the manufacture and sale of a wide range of medicinal-quality products for both human and veterinary use – not just cannabis and cannabis-containing finished products.”

According to Arcview Market Research and its research partner BDS Analytics, spending on legal cannabis worldwide is projected to hit $57 billion by 2027, as noted in an article published by Forbes (http://ibn.fm/NyZf8). The adult-use recreational market is expected to generate 67 percent of those dollars, with medical marijuana taking up the remaining 33 percent. Cannabis buyers in North America, who are currently spending a little more than $9 billion, are expected to lay down $47.3 billion by 2027, the article states.

In Canada, the government’s decision to legalize recreational cannabis for adult users by mid-2018 will soon be followed by the prospect of additional profits in cannabis-infused edibles and beverages as these items become legal in the summer of 2019 (http://ibn.fm/Ynppi). Medical cannabis has been legal in Canada since 2001. Allowing edibles and cannabis-infused beverages is expected to generate an exceptional amount of interest from the public, according to a recent survey by Dalhousie University, a public research university in Canada.

“Curiosity seems to be driving consumers to want to try a food product, an edible, and the number one choice is bakery goods,” Dr. Sylvain Charlebois, the study’s lead author, said in an interview with CTVNews.ca (http://ibn.fm/biqMa). The survey of 1,087 people found that 46 percent of Canadians would try cannabis-infused food products such as baked goods, oils and spices if they were commercially available.

Liberty Leaf President and Director William Rascan said that working with Cannabis Compliance to meet Canada’s strict GMP requirements for commercial production ensures that North Road will consistently manufacture safe, high quality finished cannabis-related products. North Road’s distribution strategy also includes a unique approach not yet seen in the cannabis industry, Rascan added.

“North Road plans to make available to both pharmacies and licensed retailers our exclusive medicinal-quality cannabis, cannabis-related products and racking jobber service,” Rascan said. “The ability for us to expand on our model by including Natural Health Products (NHPs) for human and veterinary use as well as cosmetics/beauty products, topicals, concentrates, foods/edibles and other high-quality products for distribution holds tremendous growth potential for our company.”

Investors continue to seek out and support cannabis companies – to the tune of more than $2.1 billion over the first five weeks of 2018, according to the Viridian Cannabis Deal Tracker, which tracks capital raises and M&A activity in the cannabis industry (http://ibn.fm/d5Mtt). The demand for medical, recreational and cannabis-infused products is projected to continue its upward trajectory as more states in the U.S. begin to legalize some aspect of the highly regulated plant and Canada’s new laws take effect (http://ibn.fm/96A8l).

For more information, visit the company’s website at www.LibLeaf.ca

Let us hear your thoughts: Liberty Leaf Holdings Ltd. Message Board

• Owns worldwide rights for patented formulations and drug delivery technologies
• Develops and commercializes therapeutic pharmaceuticals and nutraceuticals
• Strategic agenda to become one of world’s only vertically integrated cannabis biotechs

With worldwide rights for unique drug delivery platforms in place, Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is rapidly building a disruptive, vertically integrated biotechnology company. Advancing this agenda, the company recently announced that it has retained Cannabis Compliance Inc. to submit an application to Health Canada for a dealer’s license on behalf of Pivot’s acquisition target, Agro-Biotech Inc. (http://ibn.fm/KSY02).

In February, Pivot announced that its entry into a letter of intent for the proposed acquisition of licensed cannabis producer Agro-Biotech (http://ibn.fm/Ggy5K), which operates a fully licensed indoor hydroponic cannabis production facility that’s on track to expand its capacity 10,000 kg per year by the end of this year. Upon completion of the proposed acquisition, the dealer’s license will enable Pivot (through Agro-Biotech) to conduct research and store cannabis derivatives that are not currently covered under the Access to Cannabis for Medical Purposes Regulations.

With the acquisition of Agro-Biotech, Pivot Pharmaceuticals will control the entire manufacturing process from seed to medical derivatives and capture margins along the entire supply chain. The dealer’s license will move Pivot another step closer to becoming one of the only vertically integrated cannabis biotech companies in the world. Pivot is already a differentiated player in the Canadian cannabis industry with its unique approach to enhanced dosing and bioavailability of cannabinoids, and the company’s position in the market will only be bolstered by the acquisition.

Pivot Pharmaceuticals has assembled cutting-edge drug delivery technologies that assist both effectiveness and efficacy of medicinal cannabinoids and have potential applications across other drug categories. Pivot’s patent pending topical transdermal drug delivery technology platform, BiPhasix™, has been shown to significantly enhance the bioavailability of various drugs, leading to improved clinical outcomes. The company also acquired worldwide rights to Solmic Solubilisation Technology Platform, which allows active ingredients to become water-soluble without changing their composition or nature, significantly enhancing drug uptake.

With proven pharmaceutical and patented formulation and delivery technologies, Pivot is well positioned in an important, growing vertical of the cannabis industry and represents a compelling opportunity in the biotechnology sector. This latest announcement by Pivot enhances the opportunity.

For more information, visit the company’s website at www.PivotPharma.com

• Company is largest landowner in renowned, historically productive Canadian Cobalt Camp
• Cobalt price has risen four-fold during past two years amid worldwide demand for EVs
• More than half of all auto sales expected to be EVs two decades from now

Global society’s growing dependence on smartphones and other new technology, as nearly essential elements of daily routine, has become the foil of comedy platforms and reformative movements that offer a getaway from modern connectivity, but there’s no denying the importance of Internet-enabled tech gadgets to consumers, as well as the industries that supply them. That’s especially visible in the international rush to secure supplies of cobalt, a rare mineral that helped revolutionize the way high-tech battery cathodes move electrons in a more efficient way to minimize overheating problems. Amid the trend, Canadian company First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) is pursuing its goal of becoming the largest pure-play cobalt exploration and development company in the world.

The progression in cobalt interest has been evident as cobalt prices made a four-fold increase from their February 2016 level, rising from $21,750 per ton to a record $84,250 on March 8, when they plateaued for several days. A worldwide interest in increasing electric vehicle battery-power use as an alternative to fossil fuels has been the primary impetus behind the rising prices. At the same time, the metal has become harder to find, especially as some auto and electronics manufacturers have tried to secure their own supplies by signing long-term deals with miners. The rising demand positions First Cobalt to, potentially, relieve some of the supply pressure as it explores its holdings in Canada’s most renowned cobalt region.

By 2040, more than half of global auto sales are expected to be climate-friendly electric vehicles, as compared with just one percent last year when sales surged above one million, according to Bloomberg New Energy Finance (http://ibn.fm/mSIo6). The company’s analysts predict that boom will boost the number of EVs on the road from around three million today to more than 530 million in 2040, surpassing 15 percent of the total being driven worldwide in the 2030s (http://ibn.fm/FSvg7).

Many of the world’s tech-based industries have been hindered by their dependence on cobalt mined as a “conflict” metal commodity in the Democratic Republic of the Congo — an African nation beset by political difficulties and child labor accusations as it exploits its mineral-rich lands for foreign consumers. That includes about two-thirds of the entire cobalt supply worldwide, which continues to flow from the DRC despite the controversies.

Adding to the difficulties, the DRC’s government finalized a policy in March that increases taxes and royalties on foreign mining operations, doubling government royalties on all minerals, with the potential to more than quadruple those royalties if the country classifies a mineral as a ‘strategic substance’. That could easily include cobalt, given the DRC’s significant corner on the mineral, which is used prominently in high-tech lithium-ion battery cathodes.

First Cobalt has managed to sidestep the ethical concerns surrounding Central African cobalt mining, as well as the current budgetary difficulties brought on by the DRC’s fiscal policy changes, when the company made a strategic decision last year to abandon plans for an alliance over seven cobalt exploration properties in the Congolese region. The company instead decided to focus its efforts on the renowned Cobalt Camp in Ontario, where it has become the largest landowner in a region that historically produced the mineral and left about 50 sites that form “advanced exploration targets ready for immediate work” (http://ibn.fm/HumgH). Its ethical advantage also has the potential to translate into economic revitalization of the nearby community aptly named Cobalt.

First Cobalt was also named a 2018 TSX Venture 50 company in an annual ranking of the top 50 publicly traded companies on the TSX Venture Exchange, based on its assessment as a leader in creating shareholder value through three equally weighted criteria: market capitalization growth, share price appreciation and trading volume. First Cobalt was ranked fourth among 1,200 mining companies listed on the TSX Venture Exchange.

For more information, visit the company’s website at http://ibn.fm/FTSSF

Let us hear your thoughts: First Cobalt Corp. Message Board

• SEC-regulated offering of digital tokens
• Balance sheet funding program for fintech investments
• Issuer (MoneyTrac subsidiary) focused on fintech for cannabis industry

With a public initial blockchain offering (“PIBCO”) now underway, Global Payout Inc. (OTC: GOHE) is showcasing its innovative prowess. A PIBCO is similar to an initial coin offering, except that the coins or tokens involved are treated as securities under federal laws. As a result, the rights and benefits represented by those digital assets are subject to SEC rules. Under the PIBCO, Global Payout’s majority-owned subsidiary, MoneyTrac Technology, Inc. (“MTRAC”), will offer tokens that provide share warrants of MoneyTrac Technology Inc. The company expects that the balance sheet funding program thus created will yield returns to token holders within two years.

Initial coin offerings (“ICOs”) have had enormous success in 2017. The 10 largest were able to raise over one billion dollars, according to Bloomberg (http://ibn.fm/0zAvv). Filecoin, a data storage network, raised $257 million, while Tezos, which has developed its own secure blockchain infrastructure, raised $232 million. Amazingly, there were over 200 ICOs in 2017, some of which, very likely, were of dubious value.

This snake oil environment has prompted Pegasus Fintech to develop a process for public companies to initiate regulatory-compliant ICOs, referred to as public initial blockchain offerings to distinguish them from their unregulated brethren. Pegasus Fintech, Inc. is an innovative blockchain and token accelerator focused on delivering solutions in the financial services, blockchain and emerging cryptocurrency market sectors. With the PIBCO being subject to some SEC oversight, investor risk may be mitigated.

Compliance with federal securities laws is an essential requirement when funds are raised in the capital markets. Generally, any offer or sale of a security must either be registered with the SEC or meet an exemption. Regulation D, under the Securities Act of 1933, provides a number of exemptions from the registration requirements. However, notification of the issue and sale of the securities must be given to the SEC.

The MTRAC offering has been made under Rule 506(c) of Regulation D, which limits participation to “accredited investors” (http://ibn.fm/lmlw6). An individual is considered an “accredited investor” if he or she has earned income that exceeded $200,000 (or $300,000 together with a spouse) in each of the prior two years and reasonably expects the same for the current year or has a net worth over $1 million, either alone or together with a spouse (excluding the value of the person’s primary residence and any loans secured by the residence (up to the value of the residence)).

The funds raised in this offering will, most likely, be invested in a fashion similar to some recent business deals. For example, Global Payout’s MoneyTrac subsidiary has acquired a majority stake in PotSaver, a periodical that provides listings on discounted cannabis-related products for local dispensaries and shops. Global Payout’s MoneyTrac division is aiming to become the most recognized brand for financial technology solutions in the cannabis industry. In addition, MTRAC has entered into an exclusive partnership with GreenBox POS, LLC (“GBOX”), a blockchain company, to provide strategic sales and marketing resources. MTRAC is set to launch GBOX services in the U.S., Canada and Mexico in April 2018. GBOX’s customized payment solutions, electronic modifications and custom-built blockchain kiosk machines fall in perfectly with MTRAC’s mission of ‘Banking the Unbankable’.

Global Payout has certainly come a long way since its inception in 2009. The company quickly became a leading provider of customized prepaid payment solutions for domestic and international organizations that distributed money across the globe. In 2014, it introduced its first online payment platform, called the Consolidated Payment Gateway (“CPG”), which allowed enterprise clients to transfer money to international bank accounts, mobile accounts and prepaid card accounts. Global Payout’s CPG has become the foundation for the introduction of its new, state-of-the-art fintech payment system in 2017, for both online and mobile applications that allow account holders access to an expanded suite of financial services. A look at how the company is applying blockchain for smart solutions is available in a recent Audio Press Release (http://ibn.fm/bReR1).

For more information, visit the company’s website at www.GlobalPayout.com

Let us hear your thoughts: Global Payout, Inc. Message Board

• Research will be conducted at PACE, a leading pharmaceutical research center in Australia
• PreveCeutical’s unique technology promises to be the first FDA-approved, CBD-based nose-to-brain delivery system using a Sol-gel platform
• Groundbreaking technology outstrips the benefits of any other delivery mechanism

On March 13, 2018, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and Aurora Cannabis Inc. (OTCQB: ACBFF) (TSX: ACB) (FSE: 21P) announced that they had received three permits for the importation of cannabis plant material into Australia for research purposes. The permits were granted by the Australian Government’s Department of Health, allowing shipment from Canada by Aurora Cannabis Enterprises Inc., a wholly owned subsidiary of Aurora Cannabis Inc.

Preveceutical’s research program will be conducted at the University of Queensland’s Pharmacy Australia Centre of Excellence (“PACE”), a leading center for pharmaceutical research, education and commercialization. PACE has been granted the permits to import the dried cannabis flower and oils that will be used in the company’s innovative soluble gel (Sol-gel) drug delivery research program. It will be led by Dr. Harendra Parekh, chief research officer of PreveCeutical. The research team will test a range of cannabis strains to determine candidacy for the development and commercialization of cannabinoid-based Sol-gels.

The primary goal of the research program is to develop a nose-to-brain delivery system that will increase the bioavailability of active drug ingredients. The focus of the research is to apply Sol-gel technology to develop cannabinoid-based therapies for the relief of symptoms associated with pain, inflammation, seizures and neurological disorders. In a news release detailing the announcement, Stephen Van Deventer, chairman and CEO of PreveCeutical, said, “We are extremely excited to receive the Permits, allowing us to further our Sol-gel research program with the high quality cannabis products provided by Aurora. The goal of the Program is to cultivate a range of therapies that will benefit people with ailments such as epilepsy, pain and inflammation, safely and economically.”

“We see an important market for cannabis-based products that are more narrowly targeted at specific therapeutic areas but that are higher value add and being involved with initiatives such as PreveCeutical’s is part of our strategy to gain access to these types of products,” added Terry Booth, CEO of Aurora.

PreveCeutical believes that its cannabinoid-based nose-to-brain delivery technology, using a Sol-gel platform, will be the first to gain Food and Drug Administration approval. Its water soluable, alcohol free nasal formulation which will be developed for use by adults, children and people of certain beliefs.

PreveCeutical’s groundbreaking Sol-gel delivery system displays significant benefits over other contemporary delivery systems. It bypasses first pass metabolism in the stomach, intestines and liver, exhibiting a dramatic improvement in bioavailability, even compared to nasal sprays and alternative delivery mechanisms. Unlike other delivery systems, PreveCeutical’s Sol-gel delivery technology enables ease of application and provides long-lasting effects, all while eliminating negative side effects.

This latest research initiative comes on the back of established innovative solutions for preventive and curative therapies. The company’s first product, CELLB9®, is a Caribbean blue scorpion venom-based product that has been successfully marketed and distributed worldwide. PreveCeutical is currently in the development phase of a product based on this venom for the treatment, regulation and prevention of cancer progression. The company is also developing solutions based on the peptides derived from Caribbean blue scorpion venom for pain management, cancers, cardiovascular conditions, metabolic disorders and infectious diseases.

For more information, visit the company’s website at www.PreveCeutical.com

Let us hear your thoughts: PreveCeutical Medical Inc. Message Board

• Revolutionary sports-centric social media platform able to measure, score, monetize opinionated dialogue
• North American sports market estimated at $75 billion by 2020
• Global games market to soar even higher with 42% of $108 billion spent in 2017 consumed by mobile app users
• Multiple, partnership-based revenue streams maximize sports fan-focused meta data

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42) taps into the primal, unfiltered passion of sports fans from around the world by providing an uncensored social media platform delivered through the FANDOM SPORTS mobile app. As an aggregator, curator and instigator of both company-created and user-generated content, the FANDOM SPORTS app is designed to entertain sports enthusiasts with real-time, interactive content on a mobile only app that offers bragging rights and real-life rewards. True sports addicts will appreciate an app that allows fans to pick a fight or create their own FanFights and rule over others as they trash talk their way to victory. The FANDOM SPORTS proprietary data centric “argument engine” measures and scores opinionated dialogue, as well as establishes consensus, giving fans and users the ability to dive deeper into one-of-a-kind cultural moments, cheer on favorite sports teams and slam dunk some sweet rewards.

Building on the company’s tag line – “Pick a Fight” – the FANDOM SPORTS app provides an always fresh, authentic rush of deeper-than-surface interactive content that resonates with the targeted age demographic of 18-34. Intense sports fans aren’t afraid of stepping up to the plate to engage other users by unleashing their opinions within the app’s structured debate resolution tool coined “FanFights.” Sports-loving fans can explore, gloat, vote, invite friends, create provocative FanFight topics and play to win while inside the FANDOM SPORTS app, which is currently available in the Apple App store and coming to the Google Play store imminently. The company’s self-learning algorithm predicts and collects user preferences while building relevant personalized FanFight channels, bringing the concept of competitive, in-your-face conversation to a whole new level of sports entertainment.

The FANDOM SPORTS app is free to play (F2P) with in-app purchase and subscription capabilities. The gaming aspect of the ecosystem is built on behavioral economics and delivers multiple revenue streams by maximizing average revenue per daily active user (ARPDAU) and user-generated content (UGC), with select placement of high-impact video and moment-based marketing as part of the brand-sponsored FanFights and in-app offers. The global platform enables applications (either FANDOM SPORTS created or 3^rd party apps) to be operated in partnership with leading sports themed brands, leagues, and service providing companies within three verticals – live action, eSports, & fantasy – from around the world by supplying “interactive sports entertainment” to fans. The FANDOM SPORTS platform creates a bullet-proof snapshot of the app’s fan base through a Blockchain supported “PlayerCard” in tandem with the “Engagement Score”, which doubles as an invaluable acquisition and retention tool for its business operators. FANDOM SPORTS hosted transactions are placed on the distributed ledger, making them immutable and public to verified users interacting within the business ecosystem. Tracking this digital footprint provides extremely valuable metadata generated by users’ very dynamic behavior and sports passion.

FANDOM SPORTS’ Brand and Sponsorship partners are harnessing the affluent sports fans age 18-34 with integrated marketing content and service experience. The moments-based marketing integration will translate through FanCoin redemption, in exchange for items provided by programs established by FANDOM SPORTS and its clients. These programs are a key part of the business model and covers, as an example, the following partners; Sports Leagues, TelCo’s service offerings, and Content owners (i.e. FANDOM SPORTS provides new paying customers to the owners of pay-per-view platforms).

“Pick A Fight. Talk Trash. Get Rewarded.”

FANDOM SPORTS Media is an entertainment company that aggregates, curates and produces unique fan-focused content.

The FANDOM SPORTS App is the Company’s core product, which is the ultimate destination for unfiltered raw sports talk. The app allows passionate sports fans to unleash their primal sports passions, pick fights and earn rewards.

So download the app and bring your crew. Talking trash is better with friends. The more you invite, the more FanCoins you earn.

For more information, visit the company’s website at www.FANDOMSPORTSMedia.com

Let us hear your thoughts: FANDOM SPORTS Media Corp. Message Board